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Abstract
The anti-malarial agent cladosporin is a nanomolar inhibitor of Plasmodium falciparum lysyl-
tRNA synthetase, and exhibits activity against both blood and liver stage infection. Cladosporin 
can be isolated from the fungus Cladosporium cladosporioides, where it was believed to be 
biosynthesized by a highly reducing (HR) and non-reducing (NR) iterative type I polyketide 
synthase (PKS) pair. Genome sequencing of the host organism, and subsequent heterologous 
expression of these enzymes in Saccharomyces cerevisiae produced cladosporin, confirming the 
identity of the putative gene cluster. Incorporation of a pentaketide intermediate analog indicated a 
5+3 assembly by the HR PKS Cla2 and the NR PKS Cla3 during cladosporin biosynthesis. A 
putative lysyl-tRNA synthetase resistance gene was also identified in the cladosporin gene cluster. 
Analysis of the active site emphasizes key structural features thought to be important in resistance 
to cladosporin.
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Cladosporin (1) (also known as asperentin) is a tricyclic octaketide that is produced by 
several fungal species including Cladosporium,1–4 Chaetomium,5 Penicillium,6 Eurotium,7,8 
and Aspergillus.9 Cladosporin exhibits some interesting bioactivity, including antifungal, 
antibiotic, and plant growth inhibitory properties, as well as anti-inflammatory effects in 
mouse lung tissue.10 Most recently, cladosporin has been shown to be a potent, nanomolar, 
inhibitor of Plasmodium falciparum blood- and liver-stage proliferation.11 Although many 
antimalarial agents currently exist, endoperoxides represent the only class of molecules for 
which resistance has not significantly developed, and even these do not inhibit the 
asymptotic liver stage infection. The discovery of the bioactivity of cladosporin represents a 
promising lead for treatment of malaria, and several studies on the topic have been published 
since then.12,13
Previously in our group, we investigated the biosynthesis of several related fungal 
polyketides that belong to the resorcylic acid lactone (RAL)- and dihydroxyphenyl acetic 
acid lactone (DAL)-containing polyketides, including hypothemycin (RAL type),14 radicicol 
(RAL type),15 and dehydrocurvularin (DAL type).16–19 Biosynthesis of these polyketides 
requires cooperative action of two iterative type I polyketide synthases (PKSs): a highly 
reducing (HR) PKS and a non-reducing (NR) PKS. Based on structural similarities, we 
hypothesized that cladosporin is also biosynthesized by a HR and NR PKS. Early work in 
our group assigned the absolute stereochemistry of cladosporin.2,3 More recently, the total 
synthesis of cladosporin and its diastereomer isocladosporin, has been reported.20,21 To 
better understand PKS assembly and enable analog production via synthetic biology; we 
sought to heterologously express, and reconstitute cladosporin expression in Saccharomyces 
cerevisiae. To this end, we sequenced the genome of the producer organism Cladosporium 
cladosporioides UAMH 5063. This resulted in 30Mb of genomic information over a total of 
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764 contigs. The genomic data was annotated using Antibiotics & Secondary Metabolite 
Analysis Shell (antiSMASH v2.0).22 The software identified 50 putative secondary 
metabolite gene clusters in the genome of C. cladosporioides, seven of which encode type I 
iterative PKSs. One gene cluster in particular possessed high sequence homology to those of 
hypothemycin and zearalenone. Spliced gene sequences contained within this gene cluster 
were identified using Hidden Markov model (HMM)-based software FGENESH 
(Softberry),23 and the resulting intron-less sequences analyzed individually using BLAST 
(NCBI), Figure 1.
The HR and NR PKS contained within the gene cluster, Cla2 and Cla3 respectively, were 
cloned and expressed in S. cerevisiae BJ5464-NpgA (Supporting Information S2 and S3). 
The proteins were successfully expressed from single transformants, and with minimal 
optimization, cladosporin was isolated from double transformants at a titer of 10 mg/L after 
RP-HPLC purification (Supporting Information Figure S1). Identity of cladosporin was 
confirmed by LC-ESI-MS (Supporting Information Figure S2), using combined retention 
time matching with accurate mass matching, and NMR analysis (Supporting Information 
Figure S3 and S4). This confirmed our identification of the cladosporin gene cluster in C. 
cladosporioides. Given that S. cerevisiae is an extremely well-studied organism for 
heterologous production of other natural products such as artemisinic acid24 and 
lovastatin,25 this result constituents a significant step toward large scale production of 
cladosporin.
To further probe the biosynthesis of cladosporin in vivo, we conducted advanced precursor 
feeding studies (see Supporting Information). The necessary reduction of the C3 position of 
cladosporin led us to hypothesize that the HR PKS, Cla2, is responsible for biosynthesis up 
to the pentaketide stage, inclusive of the THP ring (Supporting Information Figure S5),3 
whereas the three subsequent ketide extensions with no reduction are catalyzed by Cla3. In 
accord with observations on other NR PKSs that require an HR PKS partner,14 Cla3 is not 
able to load and produce product on its own from malonyl CoA. Hence, the proposed 
pentaketide intermediate was synthesized as a N-acetylcysteamine (SNAC) thioester (2), 
Scheme 1 (see Supporting Information), and fed to purified Cla3, along with malonyl-CoA. 
After 24-hour incubation at room temperature, metabolites were extracted and analyzed by 
LC-ESI-MS (Supporting Information Figure S6). Identification of cladosporin (1), using 
combined retention time matching with accurate mass matching, confirmed that the 
pentaketide intermediate analog (2) is recognized by Cla3. It is likely the final product of the 
HR PKS Cla2, which remains covalently bound as a thioester until transfer to the SAT 
domain of the NR PKS Cla3. This “5+3” ketide assembly of cladosporin represents the first 
example of its type, with other DAL- and RAL-type polyketides assembled in a “4+4” 
(dehydrocurvularin)17–19 “6+3” (hypothemycin, zearalenone)14,26 and “5+4” (radicicol)15 
fashion. Thus THP ring formation appears to be catalysed by Cla2, where oxa-Michael type 
cyclization on an unsaturated thioester intermediate at the tetraketide stage would be highly 
favoured,3 Figure 1.
Encouraged by these results, we conducted further feeding studies with Cla3 (Table1, 
Supporting Information Figures S7 and S8). Surprisingly, Cla3 accepts several unnatural 
substrate analogs that do not contain the tetrahydropyran ring. The presence of a hydroxyl 
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group is vital but its stereochemical configuration is not important for recognition. However, 
carbon chains longer than ten carbons are not accepted, suggesting a hydrophobic binding 
pocket of limited size in the enzyme. Furthermore, the promiscuity of Cla3 could allow for 
the semi-synthesis of new antimalarial analogs.
We then undertook homology modelling of the product template (PT) domain using I-
TASSER,27–29 and subsequent docking studies using AutoDock Vina,30 in an effort to better 
understand how the THP ring of the natural substrate fits in the active site, Figure 2.
The most suitable homology that was used by I-TASSER as the top threading template was 
the crystal structure of the PT domain from PksA, the NR PKS responsible for biosynthesis 
of aflatoxin B1 in Aspergillus parasiticus (PDB ID 3HRQ).31 Our homolgy model indicates 
that the THP ring can be readily accommodated in the PT active site. Furthermore, as the 
ketide is extended in the PT domain, it appears to curve around on itself, up until the 
octaketide stage where C8a is now in close enough proximity to C4a to cyclize. The 
resulting aromatized intermediate could then be transferred to the TE domain, where 
hydrolysis and/or lactone formation could occur to produce cladosporin (1).
Cladosporin’s proposed antimalarial mode-of-action is inhibition of the P. falciparum lysyl t-
RNA synthetase (KRS1).11,12,32 Interestingly, a putative lysyl-tRNA synthetase gene, cla4, 
is contained within the cladosporin gene cluster. Resistance genes can often be found close 
to the biosynthetic machinery of natural products. It is possible that Cla4 may be infer 
cladosporin resistance. Hoephner et al. found that S. cerevisiae lysyl-tRNA synthetase KRS1 
is not inhibited by cladosporin, and that this resistance is related to the two key active site 
residues, Gln324 and Thr340. Replacement of Gln324 with a hydrophobic valine lead to a 5.7-
fold increase in cladosporin sensitivity, whereas replacement of Thr340 with a less bulky 
serine increased sensitivity 10.4-fold. The corresponding double mutant was 38.7-fold more 
sensitive to cladosporin. Therefore, it appears that a prerequisite of cladosporin resistance is 
the presence of a polar group at position 324 and a bulky group at position 340, a 
requirement that is met by the analogous residues in Cla4. This is further supported by the 
co-crystal structure of P. falciparum KRS1 and cladosporin, wherein the isocoumarin moiety 
of cladosporin occupies a similar orientation as the adenine of ATP, with its aromatic ring in 
a hydrophobic interaction with Val328 (Supporting Information Figure S9). Additionally, the 
THP ring of cladosporin is located directly adjacent to Ser344, where any increase in steric 
bulk would clash with the methyl substituent on the THP ring. The C. cladosporioides 
genome contains 3 putative lysyl t-RNA synthetases, Cla4, Lys2 and Lys3. Neither Lys2 nor 
Lys3 contain the Gln-Thr pair that appear necessary for cladosporin resistance, in contrast to 
Cla4.
We suggest that Cla4 may not be inhibited by cladosporin, thereby imparting cladosporin 
resistance to C. cladosporioides. It is likely that cla4 is under the control of the same 
regulation as cla2 and cla3, and when cladosporin biosynthesis is switched on, transcription 
of cla4 will then be necessary for continued protein synthesis in C. cladosporioides.
In this work, we present identification, expression and demonstration of functional activity 
of the HR and NR PKS responsible for cladosporin production in Cladosporium 
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cladosporioides. We have also identified a putative lysyl-tRNA synthetase encoded in the 
cladosporin gene cluster. This likely indicates a probable resistance mechanism in 
Cladosporium cladosporioides.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Cladosporin gene cluster in Cladosporium cladosporioides and putative biosynthesis by the 
HR PKS Cla3 and NR PKS Cla2 contained therein. KS, ketosynthase; MAT, malonyl-
CoA:ACP acyltransferase; DH, dehydratase; ψMT, pseudo C-methyltransferase; ψKR, 
structural ketoreductase; ER, enoylreductase; KRc catalytic ketoreductase; ACP, acyl carrier 
protein; SAT starter unit:ACP transacylase; PT, product template; TE, thioesterase.
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Active site cavity of Cla3 PT with docked thioacid analogs. Residues analogous to Leu1585, 
Tyr1458 and catalytic His1311, are conserved among all RAL-type PKSs. (A) Pentaketide 
analog relatively linear in the active site (B) Hexaketide starting to form a bent conformation 
(C) Constricted heptaketide analog forms a loop structure (D) Uncyclized octaketide 
thioacid analog. C8a is now only 4Å away from C4a.
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In vitro assay with Cla3. Cladosporin can be synthesized from pentaketide-SNAC thioester 
(2) and malonyl CoA.
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Table 1
Incorporation of unnatural analogs by Cla3.
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